A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-04-26
Adverse events
Grade 1 Peripheral neuropathy — outcome: UNKNOWN; onset 2022-08-14 (study day 105); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-09-15 (study day 137); relationship: N
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 139); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-09-25 (study day 147); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-26 (study day 148); relationship: not assessed
Data queries
No data queries.